INTRODUCTION .1244
The prostaglandin system is implicated in physiological and pathological responses of most tissues of the body. The background and breadth of this subject are documented in many reviews and recent symposia (15, 25, 27, 28, 51, 108, 112, 114, 135) . This review on the eNS covers advances in the past three years and concerns specifi cally the possible involvement of the prostaglandin system in the regulation of physiological and pathophysiolog ical processes.
A wide range of stimuli (hormones, enzymes, trauma, infiammation, pyrogens, immune and allergic reactions, etc) activate a plasma membrane enzyme sequence in mamm alian cells that leads to the rapid de novo synthe sis of several prostaglandin types and in certain tissues thromboxanes as well. The biologically active compounds do not accumulate intracellularly and, therefore, under physiological conditions they occur only in trace amounts in tissues and most body fl uids. Following formation, action and release, the compounds are rapidly converted by several enzymatic se quences to less active or inactive metabolites, which appear in blood and urine. Arachidonic acid, the predominant precursor unsaturated fatty acid in mammalian cells, becomes oxygenated to the prostaglandin endoperox-ides and their products. Arachidonic acid must be released from a complex lipid precursor by deacylases before it can be transformed. The biosynthesis of prostaglandins and thromboxanes by central nervous tissue and factors that affect it have been reviewed recently (42, 135, 136) . A new finding is that PGD2 is formed in excess of PGF2a by cerebral tissues of the rat (1).
CEREBROSPINAL FLUID
The existence of prostaglandin-like material in cerebrospinal fl uid (CSF) of experimental animals has been recognized for some time (25, 135) . Recent studies show CSF levels of PGF2a in human subjects without neurological disease usually to be below 100 pg ml-' (range 3�I40 pg ml-') in cell-free fluid (55, 73, 137) . Either PG� is not detectable or it is present at the same low levels as PGF2a. Thromboxane B2 is also a normal constituent (range 8�3oo pg ml-I), at least in the cat (p. Coceani, unpublished results). In contrast to most other tissues (89, 135) , the brain has very low capacity either to take up or metabolize PGF2o. and PG� to the I5-keto and 15-keto-13,I4-dihydro metabolites. Consequently, prostaglandins normally produced endogenously are primarily cleared into the general circulation through choroidal and extra-choroidal transport mechanisms (16, 55).
Marked increases in CSF PGF2a levels are found in patients with epi lepsy, meningoencephalitis, hydrocephalus, and after surgical trauma; but levels are variable even in the same patient. Likewise, patients with vascular lesions, subarachnoid hemorrhage, and stroke also show signifi cant albeit variable (200-3000 pg ml-I) increases in PGF2o. and PG� levels (22, 55, 74, 137) . Prostaglandins in the CSF may affect brain function directly or through local changes in the circulation.
CEREBRAL CIRCULATION
It is now well accepted that prostaglandins and thromboxanes contribute to vascular homeostasis through a direct action on smooth muscle in the vessel wall and, possibly, a modulation of muscle responses to neural and hormonal stimuli (27, 78, 125) . The evidence supporting this concept is as follows: (a) Vessels are endowed with an enzyme system for the synthesis of primary prostaglandins and PGI2, the latter being the predominant prostaglandin. With one exception (umbilical artery), all vessels lack the thromboxane A2 synthetic enzyme. Although these findings implicate intramural prostaglandins in the con trol of vascular tone, extramural prostaglandins may also be important, particularly under pathological conditions. Thromboxane All which is re leased in great amounts from aggregating platelets, may gain access to muscle cells in the vessel wall and cause constriction. Furthermore, prosta glandins and thromboxane A2 formed within the parenchyma of organs may act upon small resistance vessels.
The above scheme may also apply to the cerebral circulation. All primary prostaglandins and PGI2 are formed in cerebral vessels (56, 133) . Moreover, indomethacin reduces cerebral blood flow (99, 101) , which implies that vessels are normally maintained in a relaxed state by a prostaglandin. The identity of the active compound is not known. However, evidence obtained in other vascular beds and the demonstration that PG� and PGF2� are both constrictors on cerebral vessels (100, 139) suggest that this compound is PGI2• Thromboxane Az, though not formed in cerebral vessels (56), is a potent constrictor (39). In fact, thromboxane A2 is the most potent vasocon strictor among agents acting On the cerebral circulation.
According to current ideas, prostaglandins and allied compounds, be sides being involved in the normal control of cerebral blood flow, are also responsible for the hemodynamic changes occurring under certain patho logical conditions-in particular, cerebral vasospasm (132) . For example, thromboxane Az, formed in damaged brain tissue or in aggregating plate lets, is considered a prime determinant of the vasospasm-complicating thromboembolism and subarachnoid hemorrhage (39, 131). Thromboxane
Az action may be complemented by that of the prostaglandins and other vasoactive agents (5-hydroxytryptamine) (2). Indeed, thrombin stimulates PGFz� and PO� synthesis when injected intrathecally (54). Brain ischemia following head injury is possibly another prostaglandin-mediated process.
Prostaglandins, specifi cally POEz, have also been implicated in the patho genesis of migraine (58, 131). PGEz, a constrictor of intracranial vessels, dilates extracranial vessels (100); therefore, it may be involved both in the prodromal phase and in the headache phase of the migraine attack.
HYPOTHALAMIC FUNCTION
Prostaglandins have been implicated in several hypothalamic mechanisms.
Only temperature regulation, water balance, and food intake are considered here. Involvement of prostaglandins in hypothalamo-adenohypophyseal function has been discussed in recent reviews (53, 68, 70, 110).
Temperature Regulation
The subject of hypothalamic transmitters involved in thermal homeostasis has been well covered recently (29, 42, 62, 77, 99, 107, 128, 140) and does not require further elaboration here. It is sufficient to say that three com pounds, 5-hydroxytryptamine (5-HT), norepinephrine (NE), and acetyl choline (ACh) are generally assigned a key role in temperature regulation. According to most authors, body temperature is controlled through the opposing actions of 5-HT and NE on neurons in the anterior hypo thalamic/preoptic region (AH/POA). These amines have species-specific signs of action while maintaining reciprocal effects. ACh is considered a transmitter in the temperature-raising pathway in all species. The extracel lular concentration of ions within the posterior hypothalamus, and specifi cally the balance between sodium and calcium, may be an additional controlling factor. This ionic mechanism is thought to work in concert with the neurohumoral mechanism to detennine the "set-point" around which body temperature is regulated. The prostaglandins are a relatively recent addition to the fi eld of ther moregulation. Interest in these compounds dates back to the early 1970s when it was found that POEt was a potent pyretic agent (84) and that antipyretics blocked prostaglandin synthesis in various organs including brain (48, 112). These two findings implicated a prostaglandin in the genesis of fever. Research in this area developed actively and led to the demonstra tion that: (0) POEz, a normal constituent of hypothalamic tissue (70), is as potent as PGEt in producing fever (45-47,57,65,76, 86, 93, 94, 102, 106, 121) ; moreover, both compounds are like pyrogens in that their action is not infl uenced by ambient temperature (57, 65, 121, 126); (b) PGEz acts upon neurons in the AH/POA that are also the main target for pyrogens (121, 126) ; (c) thenno-sensitive neurons in AH/POA respond in the same manner to PGEz and pyrogens (117); (d) PG� fever, unlike pyrogen fever, does not abate following administration of antipyretics (24, 79, 84, 85) ; and (e) pyrogen fever is associated with elevated levels in the CSF of a prosta glandin with the biological and immunological properties of PGE2 (34, 37, 43, 44, 83, 95) . Collectively, these findings indicate that PGEz is well suited for being the "central messenger" of fever and specifically of pyrogen fever (cf 62, 80, 128) . According to current knowledge, pyrogens from outside the body (exogenous pyrogen), and foremost among them bacterial endotoxin, as well as pathological conditions causing tissue infl ammation and damage (e.g. infarction, malignancy) elicit the formation of a pyrogenic substance (endogenous pyrogen) in neutrophils and in cells of the reticuloendothelial system. The endogenous pyrogen, which is therefore a key intermediate in the sequence of events leading to fever, is then carried to the rostral region of the hypothalamus by the circulation. Because the blood-brain barrier is seemingly impermeable to endogenous pyrogen (cf 80), and because prosta glandins are rapidly removed from the circulation (cf 124), one must assume that the vessel wall is the main site where pyrogen action is translated into increased prostaglandin synthesis. Consistent with this hypothesis is the notion that vessels, including cerebral vessels, are endowed with an active prostaglandin-generating system and that hypothalamic blood fl ow is in creased during pyrogen fever (109) . The latter fi nding implies activation of prostaglandin synthesis in the vessel wall. Alternatively, PG� could be released from phagocytosing leucocytes sequestered in the capillary bed of AH/POA (128). Any pyrogen crossing the blood-brain barrier may stimu late prostaglandin synthesis in neural tissue (140) . PGE2, whether formed in the tissue of the AH/POA or from the vessels, acts at appropriate sites in the thermoregulatory pathways to elevate the "set-point" for tempera ture regulation, thus causing fever. Once its action is completed, PGE2 is either inactivated enzymatically in situ or enters the extracellular fluid and CSF whence it is transported into the circulation. Interference with the latter mechanism results in enhancement of pyrogen effects (30).
Although the experimental evidence implicating PG� in the pathogene sis of fever seems quite convincing, there have been reports contradicting the above scheme. In the monotreme, Tachyglossus aculeatus (Echidna), PGE1 and PG� are hypothermic agents, whereas endotoxin causes fever (12). Dissociation between pyrogen and PGE effects also occurs in the newborn lamb which, after appropriate sensitization, may develop fever in response to pyrogens but not in response to prostaglandins (103, 105) . A similar phenomenon has been described in the adult animal following de struction of AH/POA (126) . Potentially germane to these fi ndings is the demonstration that prostaglandin antagonists block PG� but not pyrogen fever (31).
Because pyrogen fever is susceptible to antipyretic treatment in the above experiments, a possible explanation for the inconsistencies could be that an arachidonic acid metabolite other than PG� contributes to, or is the main determinant of pyrogen effects. Consistent with this is the finding that fever following administration of arachidonic acid, while abolished by antipyret ics, is only partially blocked by prostaglandin antagonists (71). Theoreti cally, several compounds could have this role; however, available data limit the choice to two compounds, PGI2 and thromboxane A2, because prosta glandin endoperoxides and PGD2 are inactive (41, 59), and PGF2o. is a pyretic agent but only in high doses (41, 47, 86) . While no information is available on the central action of PGI2, recent work showing that levels of thromboxane B2 in the cerebrospinal fluid rise during pyrogen fever (F. Coceani, unpublished results) suggests that thromboxane A2 might be the hypothetical mediator. If so, it would not be a coincidence that intracranial bleeding, a condition in which AH/POA may be exposed to massive amounts of thromboxane A2 formed in aggregating platelets, is commonly associated with fever (113) .
Some fi ndings suggest that fever may develop independently of the pros taglandin system. In the rabbit, salicylate at certain doses has little or no effect on the febrile response to pyrogen while it completely reverses the elevation in prostaglandin levels in the CSF (34). The question remains whether the dose of salicylate used was sufficient to block the synthesis of PG� or any other pyrogenic derivative of arachidonic acid in the AH/ POA. However, more cogent evidence against the involvement of the pros taglandin system in fever is afforded by recent work in the chick (4, 5) in which it was shown that POEs are hyper-or hypothermic agents depending on the ambient temperature and that pyrogen fever is only marginally affected by indomethacin at a dose exceeding the therapeutic range (cf 48).
Etiocholanolone fever in man, which is mediated by endogenous pyrogen (19), is also resistant to antipyretic treatment.
Summing up, a large body of evidence supports the existence of a "PO� link" in the central action of endogenous pyrogen; but this prosta glandin may work in concert with another product, or more than one product, of arachidonic acid metabolism. Some forms of pyrogen fever, however, do not involve the prostaglandin system, and their central mecha nism remains obscure.
Prostaglandins probably do not contribute to normal temperature regula tion. Antipyretics, whether given systemically (24, 66, 79) or injected into the anterior hypothalamus (6, 35), produce little or no hypothermia in the afebrile animal, nor do they reverse the hyperthermia following cold stress (32, 104). Furthermore, prostaglandin levels in the CSF remain unchanged during thermoregulatory adjustments to cold or hot environments (21,33).
When present, hypothermic effects of antipyretics (cf 115) are ascribed to activation of the heat loss mechanism rather than to blockade of prostaglan din synthesis (79) . Indeed, iontophoretically applied salicylate may stimu late warm-sensitive neurons in the AH/POA of the afebrile animal (13).
The intimate mechanism of prostaglandin action in producing fever re mains a subject of speculation. It has been debated for some time (cf 28, 62) whether the prostaglandin and monoaminergic mechanisms are function ally interdependent, and this issue is far from being settled. In essence, two schemes have been proposed for linking the prostaglandins, specifically PGE1 and PG�, to the monoamines. According to one (7), monoamine actions leading to elevation in body temperature are mediated in part by a prostaglandin. In support of this concept is the finding that 5-HT stimulates the release ofPGEs from brain (64) and that epinephrine as well as 5-HT-induced hyperthermia are suppressed by antipyretics (7, 69, 82, 85) . How ever, the validity of results with the antipyretics has been questioned (36, 82), moreover, this hypothesis is not easily reconciled with the notion that monoamine effects (17,62), unlike prostaglandin effects (57, 65, 121, 126) , are affected by ambient temperature. Alternatively, it has been suggested on the basis of work with specific monoamine depletors and antagonists that monoamines are intermediates in the action of prostaglandins on tempera ture-raising mechanisms. Again, no firm conclusion can be drawn from these studies (cf 28) because positive results in one species [rabbit (20, 66, 72)] contrast with inconsistent results in another [cat (82, 126) ]. Further more, an explanation for the constancy of prostaglandin effects at different ambient temperatures must be provided before accepting this hypothesis.
Equally controversial is the question of the role of cyclic nucleotides in PGE fever. While findings in the rabbit suggest that cyclic AMP is a central mediator of PGE fever (138) , findings in the cat argue against this idea (81) .
Control of Body Water
The homeostatic regulation of body water content is dependent on the concerted action of two brain mechanisms, namely, the function of a "thirst and PGEz mimic angiotensin in stimulating ADH release (75, 129). More over, these prostaglandins share with angiotensin a dual site of action (50, 75, 129). Prostaglandin action on thirst mechanisms is a subject of contro versy. While it has been reported that PGEI and PGEz (but not PGF 2a) antagonize the dipsogenic effect of angiotensin in the rat (40, 91), the same compounds have opposite effects in the goat (3, 75). This discrepancy is unlikely due to the dose of prostaglandin used (40, 75), because the sign of responses in the rat remained the same over a wide range of doses. Differ ences may reflect a genuine species variation, the significance of which is not known.
Because low doses of PGEI and PGEz given by the ventricular route affect water balance without altering thermoregulatory neurons, responses are possibly indicative of a physiological process. This applies specifi cally to PGEz, which is present in brain. Future experiments employing blockers of prostaglandin synthesis may confirm this point. Regardless of whether responses are physiological or pharmacological, the mechanism of prosta glandin action remains to be elucidated. Prostaglandins and angiotensin, which are both vasoactive agents, may act, or interact, on blood vessels supplying target neurons in the subfornical organ and the hypothalamus. Alternatively, their action may be exerted directly on neurons. Indeed, subfornical and supraoptic neurons respond to iontophoretically applied angiotensin (92, 96) . It is still a question whether the same holds true with the prostaglandins.
Regulation of Food Intake
It is generally assumed that food intake is primarily controlled through the opposing action of two neuronal systems located in the hypothalamus: a lateral system signalling the urge for food ("feeding center"), and a ven tromedial system suppressing food intake ("satiety center") (60). Several neurohumoral agents, including the prostaglandins, have bee n implicated in the function of these neurons (cf 8). When given systemically, various prostaglandin types, including PGEt. PGEz, and PGF2a• inhibit food intake without overtly affecting behavior, body temperature, and water intake (116) . PGE1 is also effective when injected into the hypothalamus; however, its site of action varies with the species. While in the rat responsive sites are located in the anterior commissure region and the lateral hypothalamus (11), in the ewe they are located in the anterior and medial hypothalamus (10). Furthermore, in the ewe PGE1 may also stimulate feeding (10). Pros taglandin effects occur in both food-deprived and satiated animals (38), which implies a central action for these compounds.
Although these findings implicate the prostaglandins in the hypothalamic control of energy balance. some facts are inconsistent with this possibility. PG�, even though it suppresses feeding by the systemic route. has no effect on sites in the hypothalamus that are sensitive to PGE1 (10). Moreover. effective doses of PGE. by the intrahypothalamic route are in the micro gram range (10, 11. 127, 134). indicating a pharmacological rather than a physiological action. Another difficulty in accepting this idea arises from the fact that distribution of prostaglandin-sensitive sites in the hypothalamus is species-specific in spite of a seemingly constant organization of the neu ronal systems controlling feeding behavior (9).
INTERACTION WITH CYCLIC NUCLEOTIDES AND NEUROTRANSMITTERS
A large body of evidence suggests that cyclic nucleotides, and particularly adenosine 3'.5'-monophosphate (cyclic AMP). play a role in peripheral and A separate line of irivestigation suggests that PG� may modulate nora drenergic and dopaminergic transmission through inhibition of transmitter release. However, this concept is based on work in peripheral synapses (61), whereas fi ndings in the CNS are negative (130) or inconsistent (14, 111, 119).
CONCLUSIONS

Facts
Central nervous tissue has a complete system for the biosynthesis of prosta glandins and thromboxanes. The prostaglandin system is either directly or indirectly connected with neuronal activity, and its possible function is best documented in the case of hypothalamic homeostatic mechanisms.
Cerebral blood vessels synthesize 'prostaglandins, which likely contribute to normal hemodynamics. There is compelling evidence that prostaglandins are formed at multiple sites in the CNS, both neural and non-neural, and interact in a varied manner in physiological and pathological situations.
Outstanding Issues
The activity and control of synthetic enzymes in neural and non-neural constituents of CNS; the identity of compounds active at various sites; the role of PGF2a. and PGD2, which are relatively inactive in spite of being formed in excess of PG�; the likelihood of prostaglandin-degrading en zymes being confi ned to certain neuronal types and the importance of such enzymes in the termination of prostaglandin effects; and the specific involve ment of prostaglandins in synaptic events are the outstanding issues.
Prospectives
Most of the outstanding issues will be hard to resolve because of limitations in assay methodology, the multitude of compounds to be assayed, the 
